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The vesicular acetylcholine (ACh) transporter (VAChT) mediates ACh storage by synaptic vesicles. However,
the VAChT-independent release of ACh is believed to be important during development. Here we generated
VAChT knockout mice and tested the physiological relevance of the VAChT-independent release of ACh.
Homozygous VAChT knockout mice died shortly after birth, indicating that VAChT-mediated storage of ACh
is essential for life. Indeed, synaptosomes obtained from brains of homozygous knockouts were incapable of
releasing ACh in response to depolarization. Surprisingly, electrophysiological recordings at the skeletal-
neuromuscular junction show that VAChT knockout mice present spontaneous miniature end-plate potentials
with reduced amplitude and frequency, which are likely the result of a passive transport of ACh into synaptic
vesicles. Interestingly, VAChT knockouts exhibit substantial increases in amounts of choline acetyltransferase,
high-affinity choline transporter, and ACh. However, the development of the neuromuscular junction in these
mice is severely affected. Mutant VAChT mice show increases in motoneuron and nerve terminal numbers. End
plates are large, nerves exhibit abnormal sprouting, and muscle is necrotic. The abnormalities are similar to
those of mice that cannot synthesize ACh due to a lack of choline acetyltransferase. Our results indicate that
VAChT is essential to the normal development of motor neurons and the release of ACh.
Cholinergic neurotransmission has key functions in life, as it
regulates several central and peripheral nervous system out-
puts. Acetylcholine (ACh) is synthesized in the cytoplasm by
the enzyme choline acetyltransferase (ChAT) (16). Choline
supplied by the high-affinity choline transporter (CHT1) is
required to maintain ACh synthesis (52). A lack of ChAT (4,
35) or the high-affinity choline transporter (21) in genetically
modified mice is incompatible with life. ACh plays an impor-
tant role in wiring the neuromuscular junction (NMJ) during
development (38, 43). Embryonic synthesis of ACh is funda-
mental for the development of proper nerve-muscle patterning
at the mammalian NMJ, as ChAT-null mice present aberrant
nicotinic ACh receptor (nAChR) localization and increased
motoneuron (MN) survival, axonal sprouting, and branching
(4, 35).
The vesicular ACh transporter (VAChT) exchanges cytoplas-
mic ACh for two vesicular protons (37, 41). Previously reported
electrophysiological studies showed that quantal size is decreased
by vesamicol, an inhibitor of VAChT, but only in nerve terminals
that have been electrically stimulated (19, 59, 60, 63). VAChT
overexpression in developing Xenopus MNs increases both the
size and frequency of miniature-end-plate currents (54). In Cae-
norhabditis elegans, mutations in VAChT affect behavior (65).
Moreover, a decrease in VAChT expression has functional con-
sequences for mammals, as mutant mice with a 70% reduction in
the expression levels of this transporter (VAChT knockdown
[KDHOM] mice) are myasthenic and have cognitive deficits (47).
Hence, vesicular transport activity is rate limiting for neurotrans-
mission “in vivo” (18, 47).
Exocytosis of synaptic vesicle contents is the predominant
mechanism for the regulated secretion of neurotransmitters
(55). However, alternative mechanisms of secretion have been
proposed (20, 56, 61). Quantal ACh release, comparable to
that seen in developing nerve terminals, has been detected in
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myocytes and fibroblasts in culture, which presumably do not
express VAChT (14, 24). More recently, it was found that the
correct targeting of Drosophila photoreceptor axons is dis-
rupted in flies with null mutations in ChAT (64). Remarkably,
the inactivation of VAChT did not produce the same result
(64). The result suggests that the release of ACh during de-
velopment is not dependent on VAChT, perhaps because it is
nonvesicular or because vesicular storage can occur without
VAChT.
To test if the VAChT-independent secretion of ACh has any
physiological role in the mammalian nervous system, we gener-
ated a mouse line in which the VAChT gene is deleted. These
mice lack the stimulated release of ACh from synaptosomes, die
after birth, and show several alterations in neuromuscular wiring
consistent with a severe decrease in the cholinergic input to mus-
cles during development. These experiments indicate that
VAChT has an important role in maintaining activity-dependent
ACh release that supports life and the correct patterning of in-
nervation at the NMJ.
MATERIALS AND METHODS
Generation of VAChT knockout mice. The isolation of a VAChT genomic
clone was described elsewhere previously (47). This genomic clone was used to
construct a gene-targeting vector in which we added LoxP sequences flanking the
VAChT open reading frame (ORF) and the TK-Neo cassette. One LoxP se-
quence was added 260 bp upstream from the VAChT translational initiation
codon, and a second LoxP was added approximately 1.5 kb downstream from the
stop codon. The TK-Neo cassette was added immediately after the second LoxP
and was followed by a third LoxP (S1). Note that this is a vector distinct from
what we previously reported for the localization of the TK-Neo cassette (47). The
linearized targeting vector was electroporated into J1 embryonic stem cells de-
rived from 129/terSv mice, and selected embryonic stem cell clones harboring
homologous recombination (determined by PCR and Southern blotting [not
shown]) were injected into C57BL/6J blastocysts to produce chimeric mice.
Germ line transmission was achieved, and mice were bred to C57BL/6J mice to
produce heterozygote mutant mice (VAChTwt/flox). Prior to breeding VAChTflox
mice to transgenic mice constitutively expressing Cre, we bred VAChTflox mice
with CaMKIIalpha-Cre mice (Cre expression is driven by a fragment of the
CaMKIIalpha promoter, kindly donated by Scott Zeitlin [17]) in an attempt to
generate brain region-specific conditional knockout mice (these will be reported
elsewhere). However, we noted that the progeny of mating between
VAChTwt/flox,cre-CaMKIIalpha males and VAChTwt/flox females inherited a re-
combined floxed allele (VAChT-deleted allele, or VAChTdel). This allele would
be identical to that obtained by crossing the VAChTflox mice to Cre mice that
constitutively express Cre. This recombination happened because there is ectopic
expression of CaMKIIalpha-Cre in the testes, which can be detected by quanti-
tative reverse transcription-PCR (data not shown). The presence of Cre within
the testes allows the recombination of the floxed allele, probably during sper-
matogenesis, and therefore, the VAChTdel allele is transmitted to the progeny.
The ectopic expression of Cre in the testes was also previously described for
other Cre lines (e.g., synapsin-Cre [49]), indicating that this is likely to be a
common phenomenon. We backcrossed the progeny (VAChTwt/del) to C57BL/6J
mice (N4) and confirmed that they were capable of germ line transmission for the
VAChTdel allele. We then intercrossed VAChTwt/del mice to generate
VAChTdel/del mice, i.e., a potential homozygous VAChT-null mutant (see be-
low). For comparison purposes, we also obtained ChAT-null mice as a kind gift
from Kuo-Fen Lee and Fred H. Gage, Salk Institute (4).
Animals were housed in groups of three to five mice per cage in a temperature-
controlled room with 12-h light–12-h dark cycles, and food and water were
provided ad libitum. Unless otherwise stated, the experiments were always done
using embryonic day 18.5 (E18.5) embryos. All studies were conducted in accor-
dance with NIH guidelines for the care and use of animals and with approved
animal protocols from the Institutional Animal Care and Use Committees at the
Federal University of Minas Gerais and the University of Western Ontario.
Genotyping, Southern blotting, and sequencing. Genotyping by PCR was
performed using tail DNA as a template. The set of three primers used were P1
(5-TACTTGTCTGTCTGCCTGCCTGTC-3), P2 (5-AAGGAGTTGGTTGG
CCACAGTAAG-3), and P4 (5-TCATAGCCCCAAGTGGAGGG AGA-3).
Oligonucleotides P1 and P2 amplified a 247-bp fragment in the wild-type (wt)
allele, while primers P4 and P2 amplified a 329-bp fragment in the del allele. The
329-bp fragment amplified by primers P4 and P2 was purified from agarose gel
using the QIAquick gel extraction kit (Qiagen) and cloned into the pCR 2.1
vector using the TA cloning kit (Invitrogen). The sequence of the cloned frag-
ment was determined by automated DNA sequencing.
For Southern blot analysis, genomic DNA was digested with the enzymes
BamHI and SacI. Digested DNA was subjected to electrophoresis in a 1.5%
agarose gel and transferred onto a nylon membrane. After UV cross-linking,
DNA on the membrane was hybridized to the NdeI/PmeI VAChT DNA frag-
ment (see Fig. 1 for the position of the probe fragment). Detection was done
using the Alkphos direct labeling and detection system kit (GE) according to the
manufacturer’s instructions.
qPCR. For real-time quantitative PCR (qPCR), total RNA was extracted using
Trizol (Invitrogen, Sa˜o Paulo, Brazil) treated with DNase I (Ambion, Austin,
TX), and first-strand cDNA was synthesized using a High Capacity cDNA tran-
scription kit (Applied Biosystems, CA) according to the manufacturer’s instruc-
tions. cDNA was subsequently subjected to qPCR on a 7500 real-time PCR
system (Applied Biosystems, CA) using Power SYBR green PCR master mix
(Applied Biosystems, CA). For each experiment, a nontemplate reaction was
used as a negative control. In addition, the absence of DNA contaminants was
assessed in reverse transcription-negative samples and by melting-curve analysis.
The specificity of the PCRs was also confirmed by size verification of the am-
plicons by electrophoresis in acrylamide gels. Relative quantification of gene
expression was done with the 2CT method using -actin gene expression to
normalize the data. The sequences of the primers used are available upon
request.
Western blotting. Immunoblot analysis was carried out as described previously
using spinal cord extracts from E18.5 mice (47). Antibodies used were anti-
VAChT (Synaptic Systems Gottingen, Germany, and Sigma Chemical Co., Sa˜o
Paulo, Brazil), anti-CHT1 (51), anti-synaptophysin (Sigma Chemical Co.), and
anti-actin (Chemicon, CA). Images were acquired and analyzed using Image-
Quant TL (GE Healthcare).
Recombinant cDNA construct preparation, cell culture, and transfection. Rat
CHT1 subcloned into the expression vector pcDNA3.1() and mutated in
dileucine-like motif L531A was described previously (51). Human embryonic
kidney HEK293 cells were acquired from the Cell Bank, Rio de Janeiro, Brazil.
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Gibco)
and 1% penicillin-streptomycin (Gibco). For transient transfections with empty
vector (pcDNA3.1) or mutant CHT1 (L531A), HEK293 cells were seeded into
60-mm dishes (Falcon) and transfected using a modified calcium phosphate
method (23). Choline and ACh uptake assays were performed at 48 h after
transfection.
Choline and ACh uptake assays and ACh release. Choline and ACh uptake
assays were performed as described previously (50). Briefly, cells plated into
60-mm dishes were washed twice with Krebs-HEPES medium (124 mM NaCl, 4
mM KCl, 1.2 mM MgSO4, 1 mM CaCl2, 10 mM glucose, 25 mM HEPES [pH
7.4]) containing 10 mM paraoxon to inhibit acetylcholinesterase. Cells were then
incubated with Krebs-HEPES containing 10 M paraoxon and [3H]choline chlo-
ride (1 M; diluted to 1 mCi/mol) or [3H]ACh (1 mCi/mol) for 10 min at
37°C. When hemicholinium-3 (1 M) was used, the drug was added during this
incubation step and maintained during the course of the experiment. Subse-
quently, cells were washed three times with 1.0 ml of cold Krebs-HEPES with
paraoxon (10 M) and lysed with 500 l of 5% trichloroacetic acid (TCA)
solution. Lysates were centrifuged for 10 min at 10,000  g at 4°C. Pellets were
used to measure protein content (3), and radioactivity was measured in the
supernatants (100 l) by liquid scintillation spectrometry to determine choline
and ACh uptakes. In the competition assay, choline uptake was performed in the
presence of crescent amounts of ACh (3 mM, 10 mM, or 30 mM).
The TCA supernatants obtained as described above were used to determine
the [3H]ACh content (45). Briefly, TCA was removed with ether, and quaternary
amines were extracted using sodium tetraphenylboron in butyronitrile (10 mg/
ml), the organic phase separated by centrifugation was reserved, and tetraphe-
nylboron was precipitated with AgNO3 in water. The suspension was homoge-
nized and centrifuged. The organic phase was transferred into a new plastic tube
containing MgCl2 in water to precipitate excess Ag. After centrifugation, the
solution containing quaternary amines was taken to dryness under a vacuum. The
[3H]choline present in dried samples was resuspended and oxidized using choline
oxidase (Sigma-Aldrich) in glycylglycine buffer (pH 8). [3H]ACh was extracted
using tetraphenylboron in butyronitrile similarly to the procedure described
above. Tritium in the organic (predominantly ACh) and aqueous (corresponding
predominantly to choline) phases was measured by liquid scintillation spectrom-
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etry. Choline and ACh standards (0.1 to 0.5 Ci/ml) were processed in parallel
with the samples to assess yield and cross-contamination. The later values were
used to correct results of sample analyses. Protein content determined by the
method of Bradford was used to normalize the data (3). Choline or ACh uptake
into cells that was dependent on CHT1 was measured as a percentage of trans-
port in cells transfected with empty vector. Each n value represents the average
of data for triplicate samples.
KCl-induced release of [3H]ACh in brain synaptosomes. Crude synaptosomes
from whole brains of individual mice were homogenized in ice-cold buffer (0.32
M sucrose, 10 mM EDTA, Tris-HCl [pH 7.4]), and P2 pellets were obtained as
described previously (2), washed, and then incubated in a depolarizing solution
(90 mM NaCl, 50 mM KCl, 5 mM NaHCO3, 1 mM MgCl2, 1.2 mM Na2HPO4,
10 mM glucose, 20 mM HEPES, 2 mM CaCl2, 0.02 mM paraoxon [pH 7.4]) for
5 min at 30°C. Subsequently, samples were centrifuged at 5,500  g for 5 min at
4°C, and pellets were incubated in Krebs-HEPES medium (140 mM NaCl, 5 mM
KCl) containing 100 nM of [3H]choline, 5 mM NaHCO3, 1 mM MgCl2, 1.2 mM
Na2HPO4, 10 mM glucose, 20 mM HEPES, 2 mM CaCl2, and 0.02 mM paraoxon
(pH 7.4) for 15 min at 30°C for choline uptake. After centrifugation, synapto-
somes were washed three times with choline in ice-cold buffer (50 M), and
pellets were resuspended in ice-cold buffer. Each sample was separated into four
aliquots. Two aliquots were incubated in Krebs-HEPES medium, and the other
two aliquots were incubated in depolarizing solution containing hemicholinium-3
(1 M) for 5 min at 30°C. The [3H]ACh released was collected after centrifu-
gation, pellets were digested with 5% TCA, and the radioactivity of both samples
was measured using liquid scintillation counting. Total radioactivity (supernatant
and pellet) was calculated and then normalized by protein content. For each
sample, the average values obtained under depolarizing or nondepolarizing con-
ditions was divided for the total radioactivity. The release of newly synthesized
[3H]ACh is predominant under this condition (2); the results are shown as
fractional release above baseline release obtained under nondepolarizing condi-
tions.
Tissue ACh measurements. Brains were dissected rapidly, homogenized in 5%
TCA, and centrifuged (10,000  g for 10 min) at 4°C. Supernatants were frozen
at 80°C until use. For ACh determinations, TCA was removed with ether, and
a chemiluminescent assay was done with choline oxidase as described previously
(44). The data are presented as means and standard errors of the means (SEM).
One-way analysis of variance (ANOVA), followed by Bonferroni’s test, was used
to analyze the differences in tissue ACh concentrations in VAChTwt/wt,
VAChTwt/del, and VAChTdel/del mice; a P value of 0.05 was considered to be
statistically significant.
Electrophysiology. Electrophysiology experiments were performed similarly to
methods described elsewhere previously (47). Hemidiaphragms were isolated
from E18.5 embryos, and the muscle with attached nerve was pinned to a Sylgard
pad in a 5-ml acrylic chamber continuously perfused at a rate of 1 ml/min with
Tyrodes solution containing 137 mM NaCl, 26 mM NaHCO3, 5 mM KCl, 1.2 mM
NaH2PO4, 1.3 mM MgCl2, 2.4 mM CaCl2, and 10 mM glucose equilibrated with
95% O2–5% CO2 at pH 7.4. During recording, tetrodotoxin (3 M) was included
to avoid contractions. Microelectrodes were fabricated from borosilicate glass
and had resistances of 8 to 15 M	 when filled with 3 M KCl. Standard intracel-
lular recording techniques were used to record miniature end plate potentials
with an Axoclamp-2A amplifier. Recordings were band-pass filtered (0.1 Hz to
10 KHz) and amplified 200 times prior to digitization and acquisition on an IBM
computer running WinEDR (John Dempster, University of Strathclyde). The
membrane potential was recorded and used to correct MEPP amplitudes and
areas to a standard resting potential of 60 mV. At the end of experiments, 5
M d-tubocurarine was applied to verify that the observed events were due to
nicotinic receptors.
FM1-43 imaging. FM1-43 imaging experiments were performed as described
previously (47) except that a fixable FM1-43 analog was used. Briefly, dia-
phragms from E18.5 mice were dissected and mounted onto a Sylgard-lined
chamber containing mouse Ringer solution with the following composition: 135
mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 1 mM
Na2HPO4, and 11 mM D-glucose. Solutions were aerated with 95% CO2–5% O2,
and the pH was adjusted to 7.4. FM1-43fx (8 M) was used to stain recycling
synaptic vesicles during stimulus with a high-K solution (60 mM KCl) for 10
min with 16 M d-tubocurarine to prevent contractions. After stimulation, the
preparation was maintained in normal K solution for 10 min to guarantee
maximal FM1-43fx uptake. Excess FM1-43fx adhering to the muscle cell plasma
membrane was removed during a washing period in mouse Ringer solution not
containing FM1-43fx for at least 40 min; 16 M d-tubocurarine was present to
prevent muscle contraction. Advasep-7 (1 mM) was added during the washing
period after FM1-43fx staining to reduce background fluorescence. Diaphragms
stained with FM1-43fx were fixed with 4% paraformaldehyde for 40 min and then
mounted onto slides and examined by fluorescence microscopy on either an
Axiovert 200 M microscope equipped with a 40 water immersion objective
using the Apotome system or a Leica SP5 confocal microscope using a 63 water
immersion objective and an argon laser (488 nm) for excitation. The spectrum
emission was set from 510 to 620 nm. During image acquisition, whole hemidia-
phragms were scanned, and the images were obtained from muscle areas with
stained NMJs. The total number of junctions per hemidiaphragm was defined by
the sum of junctions observed in each image after scanning the entire muscle.
The density of junctions was determined by the ratio of the number of junctions/
total area (mm2). The nerve terminal area was measured using Image J, and
the size of each terminal was expressed in pixels2. Data were analyzed using
an unpaired t test. A P value of 0.05 was considered to be statistically
significant.
Immunofluorescence. Immunofluorescence was performed as described pre-
viously (4). Briefly, whole-mount diaphragms from embryos were rapidly dis-
sected and fixed in 4% paraformaldehyde–phosphate-buffered saline (PBS) (pH
7.4) for approximately 3 days. Tissues were cryoprotected with 10% sucrose–4%
paraformaldehyde, frozen with isopentane over dry ice, and kept at 80°C until
use. Muscles were rinsed two times in PBS, incubated with a 0.1 M glycine–PBS
solution for 1 h, and blocked in incubation buffer (150 mM NaCl, 0.01 M
phosphate buffer, 3% bovine serum albumin, 5% goat serum, and 0.01% thimer-
osal) overnight at 4°C. Tissues were immunostained with anti-VAChT (rabbit
polyclonal; Sigma Chemical Co.), anti-CHT1 (51), or anti-neurofilament 150
(rabbit polyclonal; Chemicon) in incubation buffer overnight at 4°C. Following
three washes of 1 h each with PBS–0.5% Triton X-100, muscles were incubated
with Alexa Fluor 546-conjugated goat anti-rabbit antibody (Molecular Probes)
and Alexa Fluor 488-conjugated 
-bungarotoxin (Molecular Probes) in the
buffer described above overnight at 4°C, and the washing step was repeated.
Diaphragms were flat mounted in Hydromount medium, and images were col-
lected with an Axiovert 200 M microscope using the Apotome system or a Leica
SP5 confocal microscope to acquire optical sections of the tissues. Quantitative
analyses of nAChR or CHT1 fluorescence were carried out with Metamorph
software (Molecular Devices, Downingtown, PA). For each set of experiments, a
threshold was calculated by using a background area of the image. This threshold
value determined for VAChTwt/wt was applied to images obtained with other
genotypes, and the total fluorescence intensity (integrated intensity) for bunga-
rotoxin-labeled nAChR or terminals labeled by CHT1 antibody was then de-
tected automatically. To count the number of positive terminals or junctions,
adjacent sections of the entire muscle were obtained, and the numbers of positive
labeled structures were counted with Metamorph similarly to the above-
described experiments with FM1-43.
MN quantification. Adult pregnant females were anesthetized with ketamine-
xylazine (70 mg/kg and 10 mg/kg, respectively) intraperitoneally and sacrificed by
cervical dislocation. Embryos were removed quickly, and spinal cords were re-
moved and immersed in Bouins fixative for 24 h prior to being processed for
paraffin embedding. Paraffin blocks were serially sectioned, with sections placed
onto microscope slides and stained with thionin. MNs were counted as described
previously (12).
In vivo analysis of muscle function. Locomotor activity, grip force, and wire
hang tests were performed essentially as described previously (15, 47).
FIG. 1. Generation of VAChTdel/del mice. (A) Generation of VAChT del mice using the Cre-LoxP system. Boxes represent the different exons
of ChAT or VAChT. Open boxes represent the ORF of VAChT and ChAT. Note that the VAChT gene is within the first intron of ChAT.
(B) Schematic representation of the VAChT gene locus, the floxed allele, and the del allele. P1, P2, P3, and P4 indicate the positions of PCR
primers used for genotyping. (C) Sequence analysis of the 329-bp fragment amplified with primers P2 and P4. Restriction sites and LoxP sequences
are indicated. (D) VAChT mutant mice (VAChTdel/del) died rapidly after birth in cyanosis (not shown). Embryos from E18.5 exhibited flaccid limbs
and kyphosis (hunchback). (E) Southern blot analysis confirmed the presence of the del allele in VAChT mutant mice. (F) Genotype of VAChT
mutant mice by PCR.
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RESULTS
Generation of mice null for VAChT. We have generated
mice in which the VAChT ORF was deleted using Cre-Lox
technology (Fig. 1A and B). The deletion of the VAChT ORF
was confirmed by DNA sequencing (Fig. 1C), and we named
the VAChT-deleted allele VAChTdel. The posture of
VAChTdel/del mice at E18.5 resembles that of ChAT-null mice,
with flaccid limbs and signs of slight kyphosis (Fig. 1D).
VAChTdel/del mice die rapidly in cyanosis within 2 to 5 min
after birth. Southern analysis (Fig. 1E) and PCR genotyping
(Fig. 1F) confirmed the presence of the del allele in heterozy-
gous and homozygous VAChT mutant mice. These mice are a
novel mutant line distinct from the one that we have previously
described and that presents close to 70% and 45% reductions
in VAChT expression (VAChT KDHOM and VAChT KDHET,
respectively). Contrary to the mouse line reported here
(VAChTdel/del), the VAChT KD lines survive to adulthood
(47).
To confirm that the genetic manipulation that putatively
deleted the VAChT ORF indeed suppresses VAChT mRNA
expression, we used qPCR and E18.5 embryos (Fig. 2A).
VAChTwt/del mouse brain presented a 50% decrease in the
VAChT mRNA level compared to VAChTwt/wt littermate con-
trols. No VAChT mRNA was detected in VAChTdel/del mouse
brain. The reverse transcription-PCR amplicons were also
separated by electrophoresis in a polyacrylamide gel.
VAChTdel/del mice generated no DNA fragment correspond-
ing to VAChT (Fig. 2A, inset gel). VAChTwt/del mice exhibited
FIG. 2. VAChT expression and ACh release in VAChTdel/del E18.5 mice. (A) Quantitative analysis of VAChT mRNA levels by qPCR. PCR
products were run in a polyacrylamide gel. *, statistically different from wt; **, statistically different from wt/del {one-way ANOVA with Bonferroni
post hoc [F(2,6  920)]; P  0.0001; n  4}. Lanes labeled with a  show the respective negative control without the sample. (B) Western blot
analysis of VAChT, synaptophysin, and tubulin in spinal cord extracts. (C) Average values for the amount of VAChT from densitometric analyses
of several Western blots. Tubulin immunoreactivity was used to normalize protein loading. Data are presented as percentages of VAChTwt/wt
levels. *, statistically different from wt; **, statistically different from wt/del {one-way ANOVA with Bonferroni post hoc [F(2,9  927.9)]; P 
0.0001; n  4}. (D) Effects of KCl-induced depolarization on [3H]ACh release from synaptosomes. *, statistically different from wt/wt (P  0.05
by t test). (E) MEPPs from the NMJ. MEPPs recorded in VAChTwt/del muscle show no significant change in amplitude compared to VAChTwt/wt
mice. VAChT-null mice showed the existence of scarce MEPPs with decreased amplitude compared to VAChTwt/wt and VAChTwt/del mice.
(F) d-Tubocurarine abrogated MEPPs in both VAChTwt/wt and VAChTdel/del mice.
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a 50% decrease and VAChTdel/del mice exhibited a 100% de-
crease in VAChT protein levels assayed by Western blotting of
spinal cord extracts (Fig. 2B and C). The amount of synapto-
physin, a protein present in synaptic vesicles, was unchanged in
the spinal cord of VAChTdel/del mice (Fig. 2B).
To investigate the importance of VAChT for the evoked
secretion of ACh, we prepared crude synaptosomes from the
forebrain of E18.5 wt and homozygous mutant mice. We la-
beled ACh in these synaptosomes with the precursor [3H]cho-
line and monitored the release of labeled neurotransmitter as
previously described (2, 26, 27, 32). VAChTdel/del mice are
capable of producing ACh (see Fig. 5). KCl depolarization was
able to increase the release of [3H]ACh in synaptosomes ob-
tained from wt mice but not from VAChTdel/del mice (Fig. 2D).
Therefore, this experiment indicates that in the absence of
VAChT, depolarization-evoked ACh release is hindered.
In order to analyze ACh secretion under nondepolarizing
conditions, we performed electrophysiological analysis of the
nerve-muscle diaphragm preparation. Figure 2E shows MEPPs
recorded from NMJs of VAChTwt/wt, VAChTwt/del, and
VAChTdel/del E18.5 mice. VAChTwt/del mice presented no
change in the amplitude of MEPPs compared to control mice
(0.99  0.09 mV for wt/wt and 0.92  0.09 for wt/del for 31
MEPPs in three and four mice, respectively). Surprisingly, we
could detect small-amplitude MEPPs in the NMJ from E18.5
embryos of VAChTdel/del mice (Fig. 2E). These experiments
were difficult to perform, as the frequency of MEPPs in
VAChTdel/del mice was noticeably low compared to that of
VAChTwt/wt embryos (del/del  0.0072  0.0009 Hz [11
MEPPs obtained from four fibers from two mice]; wt/wt 
0.0308  0.002 Hz [three fibers from three mice]; wt/del 
0.0364  0.008 Hz [six fibers from four mice]). MEPPs from
VAChTdel/del mice were of smaller amplitude (0.54  0.07
mV). However, given the overt morphological changes at the
NMJs from E18.5 VAChTdel/del mice (see Fig. 6, 7, and 8),
both pre- and postsynaptic contributions to these changes are
likely. Treatment of NMJs from control littermates and ho-
mozygous VAChT mutants with d-tubocurarine (5 M) abol-
ished miniature detection, indicating that the MEPPs were
likely recorded due to the activation of nAChR (Fig. 2F). In
agreement with the fact that VAChTwt/del mice presented no
alteration in MEPPs at the NMJ, adult VAChTwt/del mice
presented no overt neuromuscular dysfunction that could be
detected in a test of fatigue or grip force (Fig. 3A and B). In
addition, spontaneous locomotor activity was unchanged in
VAChTwt/del mice (Fig. 3C).
We considered whether ACh uses another type of trans-
porter to load synaptic vesicles in the absence of VAChT. One
candidate is CHT1, which has been found to reside predomi-
nantly in synaptic vesicles by us (15, 50–52) and others (22, 36).
Like other secondary active transporters for aqueous solutes,
CHT1 probably functions bidirectionally (33). “Reverse trans-
port” by CHT1 would be required to mediate ACh uptake by
synaptic vesicles. We tested the possibility that CHT1 trans-
ports ACh in addition to choline by using a cell line expressing
recombinant CHT1. We were not able to do the test in nerve
terminals per se, as the pharmacological blockade of CHT1
would decrease ACh synthesis and potentially produce effects
on small MEPPs not due to the inhibition of vesicular CHT1.
To untangle the multiple possible roles of CHT1, we used a
mutant form of CHT1 (L531A) that does not undergo endocy-
tosis, and which remains predominantly on the cell surface, to
transfect HEK293 cells. The strategy is expected to maximize
ACh uptake by transfected cells should CHT1 be able to trans-
port ACh (51). As expected, transfected cells took up fourfold-
more choline than did nontransfected cells (Fig. 4A) (51). ACh in
concentrations similar to those found in the cytoplasm of cholin-
ergic terminals (41) inhibited choline uptake, indicating a good
likelihood that ACh competes with choline for binding to CHT1
(Fig. 4B). However, the transfected cells took up no more ACh
than did nontransfected cells (Fig. 4C). The results demonstrate
that CHT1 does not significantly transport ACh, and thus, they do
not support the possibility that CHT1 mediates the uptake of
ACh by synaptic vesicles.
The results leave open the possibility that a passive transport
system similar to that described previously for isolated cholinergic
vesicles of Torpedo is present in mammalian synaptic vesicles (8).
In the right circumstances, even the passive uptake of ACh by
synaptic vesicles might be sufficient to generate the small MEPPs
observed here. Indeed, recent experiments by Parsons and col-
laborators using synapse-like microvesicles from rat PC12 cells
found that intact vesicles loaded with ACh lose their neurotrans-
mitter content even when a high-affinity analog of vesamicol com-
pletely blocks VAChT. The result demonstrates an ACh leakage
FIG. 3. Neuromuscular function in VAChTwt/del mice. (A) Grip
force measured for VAChTwt/wt and VAChTwt/del mice. There is no
significant difference between the two genotypes. (B) Time spent hang-
ing upside down from a wire netting for VAChTwt/wt and VAChTwt/del
mice. No significant difference was observed. (C) Spontaneous loco-
motor activity is not changed between the genotypes.
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mechanism in synapse-like microvesicles that might be bidirec-
tional (S. M. Parsons, personal communication).
However, in order for the passive uptake of ACh by syn-
aptic vesicles to be possible in VAChTdel/del mice, cytoplas-
mic stores of ACh must be maintained. In the absence of
vesicular storage, many neurotransmitters are degraded
(62), but in C. elegans, the mutational inactivation of
VAChT leads to an increase in the ACh content of the worm
(29). Therefore, we measured the amount of intracellular
ACh in the brains of mutant mice. In E18.5 embryos, the
amount in VAChTdel/del mice was more than fivefold greater
than that in VAChTwt/wt mice (Fig. 5A). There was also a
clear tendency for the level of ACh in the brain of VAChTwt/del
embryos to be increased compared to that of control wt mice
(Fig. 5A). In adult VAChTwt/del mice, the ACh content was
significantly increased compared to that of control wt mice
(Fig. 5B). Because vesicles in VAChTdel/del mice are likely
depleted of ACh, the concentration increase for ACh in the
cytoplasm of cholinergic terminals is probably greater than
what the bulk analysis indicates. Hence, an increased concen-
tration of cytoplasmic ACh in VAChTdel/del mice might sup-
port the passive uptake of ACh into synaptic vesicles and
produce small MEPPs.
Why is there so much more ACh in VAChTdel/del mice?
One possible explanation is increases in the amounts of
either ChAT or CHT1, which are involved in the synthesis of
ACh. To test for this possibility, we performed qPCR anal-
ysis of E18.5 embryos. Transcript levels for ChAT were
increased in a gene dosage-dependent way (Fig. 5C).
VAChTwt/del mice had nearly twofold-more ChAT mRNA
than their control littermates, whereas VAChTdel/del mice
had nearly fourfold more (Fig. 5C). In addition, we found
that VAChTdel/del mice had nearly twofold-more CHT1
mRNA than control littermates, whereas VAChTwt/del mice
had no significant change (Fig. 5D). At the protein level, we
also detected an increase in the amounts of ChAT and
CHT1 in homozygous mutant animals (Fig. 5E and F).
These observations suggest that increases in ChAT and
CHT1 expression levels likely underlie the increase in the
amount of ACh in VAChTdel/del mice.
Abnormal neuromuscular patterning is a major feature of NMJ
developed in the absence of ACh (4, 35). In VAChTdel/del mice,
nerve terminals have fivefold-more ACh but lack the protein
responsible for the active storage of the transmitter in vesicles.
Does a lack of VAChT affect NMJ development? Can the lack of
VAChT be compensated by the excess intraterminal ACh in
VAChT mutants? In order to answer these questions, we evalu-
ated nerve branching, nAChR localization, and the genesis of
nerve terminals by labeling the NMJ of wt, VAChTwt/del, and
VAChTdel/del mice with distinct markers. To begin, we tested
whether NMJs of VAChTdel/del mice showed immunoreactivity
for VAChT. We found no VAChT immunoreactivity, as expected
(Fig. 6A); in comparison, CHT1 immunolabeling was easily de-
tected (Fig. 6B). Interestingly, analysis of nAChR labeling
using fluorescent 
-bungarotoxin–Alexa Fluor 543 (BTX-
543) (Fig. 6, red) suggested an altered nAChR distribution
(Fig. 6A and B and higher magnification in C). Indeed,
clusters of nAChR labeled with BTX-543 showed stronger
labeling and a larger area in VAChTdel/del mice than the
corresponding labeling in control and VAChTwt/del mice
(Fig. 6C and D) (the increase in labeling was close to 70%).
The rescue of MNs from physiologically programmed cell
death that follows the blockade of neuromuscular activity dur-
ing development is a well-known phenomenon (38, 39). The
disturbance of ACh synthesis also affects MN apoptosis (4). In
order to test if in the absence of VAChT MNs went through
the normal wave of apoptosis, we counted lumbar MNs from
wt and VAChTdel/del E18.5 embryos (Fig. 6E). Of note, there
was a significant increase in the number of MNs in VAChT
mutant mice compared to wt controls (36%), suggesting that
VAChT-independent ACh secretion did not generate the mus-
cle activity necessary for the programmed cell death of MNs
during development. The increase in MN survival was similar
to but somewhat less severe than that observed for ChAT-null
mice (Fig. 6E) (51% increase in the number of neurons com-
pared to wt controls).
To examine if the enhanced nAChR labeling and enhanced
MN numbers are accompanied by an increase in the number of
nerve terminals in VAChTdel/del mice, we quantified the num-
ber of CHT1-positive nerve terminals. Immunoreactivity for
CHT1 (Fig. 7A) was increased at the NMJ, confirming the
biochemical data shown in Fig. 5D and F. We also quantified
the number of CHT1-positive nerve terminals, and we detected
a significant increase in the number of CHT1-positive nerve
FIG. 4. (A) Choline uptake in HEK293 cells transiently transfected
with empty vector (pcDNA3.1) or L531A CHT1 cDNAs. The data
represent the means  SEM of data from five independent experi-
ments (in duplicates) and are normalized to data for cells expressing
empty vector (pcDNA3.1). *, significant difference (P  0.05 by t test).
(B) ACh competition assay using HEK293 cells transiently transfected
with empty vector (pcDNA3.1) or L531A CHT1 cDNAs. The data
represent the means  SEM of data from four independent experi-
ments and are normalized to data for cells expressing the empty vector
(pcDNA3.1). *, significantly different from control uptake. (C) ACh
uptake in HEK293 cells transiently transfected with empty vector
(pcDNA3.1) or L531A CHT1 cDNAs. The data represent the
means  SEM of data from three independent experiments and are
normalized to data for cells expressing the empty vector (pcDNA3.1).
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endings in VAChT-null mutants (Fig. 7B). To further test if
the nerve endings in the diaphragm of VAChTdel/del mice were
able to undergo exocytosis-endocytosis, we used a form of the
activity-dependent dye FM1-43, FM1-43fx, that can be used for
protocols requiring tissues to undergo fixation. Preparations to
be stained with FMI-43fx underwent KCl-mediated depolar-
ization as described previously (47, 53) and were then washed
and fixed prior to the quantification of fluorescently labeled
nerve terminals. The results show that synaptic vesicles in
VAChTdel/del mice undergo exocytosis-endocytosis. Moreover,
muscles from homozygous mutants have an increased density
of stained nerve terminals compared to control wt mice (40%
increase) (Fig. 7C and D). Figure 7E shows an example of
terminals labeled with FM dye, and Fig. 7F indicates that in
addition to an increase in the number of terminals, the area
of the individual terminals labeled with FM1-43 from
VAChTdel/del mice is also increased compared to that from
VAChTwt/wt mice (P  0.0018). The increase in the number of
nerve terminals appears to be a consequence of the complete
loss of VAChT, as VAChT KDHOM mice that preserve 30% of
normal levels of the transporter show no such increase (48;
data not shown). VAChT KDHOM mice also did not show an
increase in the number of MNs, suggesting that reducing
VAChT levels by up to 70% can still support enough release of
neurotransmitter during development to maintain the program
of MN cell death (data not shown).
To further examine axonal targeting at the NMJ in the
absence of VAChT, we labeled diaphragms from wt,
FIG. 5. Neurochemical alterations in VAChTdel/del mice. (A) Intracellular ACh contents in brains of VAChT mutant mouse embryos. Data are
means  SEM (three to five mice). An asterisk indicates a statistically significant difference by one-way ANOVA with Bonferroni post hoc test
[F(2,10  12.72)]. (B) Intracellular ACh content in brains from adult VAChTwt/wt and VAChTwt/del mice (n  4 to 6 brains) (***, P  0.001).
(C) ChAT mRNA levels detected by qPCR from E18.5 mouse brains [F(2,9  18.28)] (n  4). (D) CHT1 mRNA levels detected by qPCR from
E18.5 mouse brains. *, statistically different from VAChT
wt/wt mice; **, statistically different from VAChT
wt/del mice [F(2,11  12.52)] (n  5).
(E) ChAT and CHT1 protein expression in E18.5 spinal cords. (F) Quantification of protein expression (three to four animals) (P  0.05) [CHT1
F(2,6)  35.21; ChAT F(2,15)  4.599]. *, statistically different from wt/wt; **, statistically different from wt/del.
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VAChTwt/del, and VAChTdel/del mice with an anti-neurofila-
ment antibody (Fig. 8, red) and nAChR with BTX-Alexa Fluor
488 (Fig. 8, green). These experiments show that there is no
difference in axonal branching between wt and VAChTwt/del
mice. Axon branches from the nerves labeled with the anti-
neurofilament antibody were of the characteristic size and gen-
erally contacted a cluster of nAChR (Fig. 8). In contrast,
VAChTdel/del mice had an increase in axonal sprouting and
branching that contacted improperly arranged nAChR clusters
(Fig. 8). The morphology of the NMJ from VAChTdel/del mice
was remarkably similar to that reported for ChAT-deficient
mice. In fact, in hematoxylin- and eosin-stained muscles, we
note that sheets of condensed parallel fusiform nuclei with
abundant myofibrillar tissue could be easily discerned in
VAChTwt/wt and VAChTwt/del mice (Fig. 9A and B). In con-
trast, myofibrilar tissue was replaced with fragmented myofi-
brils in VAChTdel/del mice (Fig. 9C). In some cases, there was
a complete loss of normal architecture in mutant muscles, and
degenerated myofibrils were replaced with fibrotic and fatty
tissue (Fig. 6C). Relative to the controls, skeletal muscles from
VAChTdel/del mice showed marked atrophy. These findings
suggest that in the absence of VAChT, despite the nerve ter-
minals having increased ACh contents, the outcome for NMJ
development was as severe as the lack of ACh synthesis.
DISCUSSION
The present work addresses the role of VAChT in sustaining
the release of ACh. We found that VAChT is fundamental for
ACh release in the brain and the NMJ. Moreover, in the
absence of the vesicular transport of ACh, there are profound
effects on axons, terminal numbers, and synaptic and muscle
morphology at the NMJ. Indeed, VAChT-null mice, despite
presenting fivefold-more ACh than control mice, recapitulate
the NMJ phenotype found in mice that cannot synthesize ACh
due to a lack of ChAT. These observations bear important
consequences for understanding how developing synapses
function and the mechanisms by which transmitter secretion
during development regulates synaptic targeting.
VAChT knockout mice do not survive postnatally. The phar-
macological inhibition of VAChT causes paralysis and death
compatible with an NMJ blockade (5), indicating that interfer-
ence with VAChT might be lethal. Given the observations that
ChAT-null mice have abnormal NMJ development (4, 35), the
question arises of whether it is just the presence of ACh that is
required or if the VAChT-mediated storage of ACh during
development is also important. Previous experiments with
munc18-1 null mice, which have no regulated secretion of a
neurotransmitter, also suggested that NMJ development is reg-
FIG. 6. Alterations in MN number and in NMJ morphology in VAChTdel/del E18.5 mice. (A) VAChT immunoreactivity was easily detected in
presynaptic termini of VAChTwt/wt and VAChTwt/del diaphragms but was absent in VAChTdel/del mice. (B) CHT1 immunoreactivity was detected
in all genotypes, although VAChTdel/del mice showed an altered distribution of nerve endings (see below and Fig. 5). (C) Abnormal distribution
of nAChR in VAChTdel/del NMJs. Images show that nAChRs from VAChTdel/del mice present stronger labeling and are distributed over a broader
region than those from wt and VAChTwt/del mice. (D) Quantification of nAChR fluorescence. Four independent experiments were performed, and
the results are expressed as means  SEM. An asterisk indicates a statistically significant difference (one-way ANOVA with Bonferroni post hoc)
[F(2,20  5.632)]. A.U., arbitrary units. (E) The number of lumbar MNs was significantly increased in VAChT and ChAT-null mice. Clear bars,
wt mice; dark bars, homozygous mutant mice.
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ulated by synaptic vesicle exocytosis, although for these mu-
tants, it has not been established whether ACh synthesis and
storage are affected (28). A number of previously reported
studies suggested that distinct pathways of ACh secretion
might exist at cholinergic synapses (56, 60, 61, 64). Moreover,
vesamicol-independent ACh release, presumably from synap-
tic vesicles, can be detected in response to pharmacological
treatments (2, 7, 10, 11, 46). Hence, if VAChT-independent
mechanisms of ACh release have functional significance, they
might partially compensate for the lack of the transporter in at
least some of its physiological roles.
Interestingly, experiments with an independent mouse line,
VAChT KDHET mice, that have close to a 40% reduction in
VAChT expression levels showed that a moderate reduction in
the level of VAChT causes no neuromuscular phenotype and
only small changes in neuromuscular neurotransmission (47).
Similar results were obtained with VAChTwt/del mice in the
present report, suggesting an important safety mechanism at
FIG. 8. Altered morphology at the NMJ of VAChTdel/del E18.5
mice. Whole diaphragms were stained with anti-neurofilament anti-
body (red), and nAChRs were labeled with 
-bungarotoxin (green).
Confocal stacks were obtained, and maximal projections are shown in
the images. The image is representative of three experiments. Note the
large increase in axonal sprouting in VAChT-null mice.
FIG. 7. Synaptic alteration in VAChTdel/del E18.5 mice. (A) Quantification of CHT1 fluorescence (arbitrary units [A.U.]) in nerve terminals.
An asterisk indicates a statistically significant difference (one-way ANOVA with Bonferroni post hoc test) [F(2,20  5.632)]. (B) Density of nerve
terminals immunolabeled for CHT1 in hemidiaphragms from VAChTwt/wt, VAChTwt/del, and VAChTdel/del mice. *, statistically different by ANOVA with
Bonferroni post hoc test [F(2,17)  18.43]. (C) Density of nerve terminals stained with FM1-43fx in hemidiaphragms of VAChTwt/wt and VAChTdel/del
mice (*, P  0.0218 for VAChT
wt/wt versus VAChTdel/del mice by unpaired t test; n  6). (D) Number of nerve terminals stained with FM1-43fx per
hemidiaphragm (*, P  0.0260 for VAChT
wt/wt versus VAChTdel/del mice by unpaired t test; n  6). (E) Representative images of NMJs stained with
FM1-43fx in hemidiaphragms of VAChTwt/wt and VAChTdel/del mice (scale bar, 10 m). (F) Average area of single nerve terminals in mouse
hemidiaphragms stained with FM1-43fx (*, P 0.0018 for VAChT
wt/wt versus VAChTdel/del mice by unpaired t test). At least 30 end plates were analyzed
for each genotype.
VOL. 29, 2009 VAChT AND NEUROMUSCULAR DEVELOPMENT 5247
the NMJ that allows decreased VAChT expression to be com-
pensated. However, VAChT KDHOM mice, with close to a
70% decrease in VAChT protein levels, do show alterations in
neuromuscular neurotransmission and motor function (47). It
should be noted, however, that synapses in the central nervous
system are more sensitive to reductions in VAChT expression,
and both VAChT KDHET mice (47) and VAChTwt/del mice
(our unpublished observations) present selective cognitive def-
icits in object recognition memory.
Despite this substantial compensation, the rapid postnatal
death of VAChTdel/del mice argues that the active storage of
ACh by this transporter is critical at the NMJ, as the mice
succumb to respiratory failure. In agreement with this conclu-
sion, synaptosomes from VAChTdel/del mice do not release
newly synthesized ACh in response to depolarization. Lethal
mutants of VAChT have also been generated in Drosophila
melanogaster. These mutants are apparently expressed as well
as wt alleles, but they have affected VAChT transport activity
(31). Lethal alleles of unc-17 in C. elegans have also been
identified, indicating that VAChT is critical for survival in
several organisms (1).
VAChT regulates cholinergic synaptic development. Whereas
it is clear that ACh storage by VAChT is important for motor
function, it is possible that during development, other mecha-
nisms of ACh release, which are independent of this trans-
porter, might become relevant. In nerve-muscle cocultures, a
nonquantal release of ACh can be detected in developing
growth cones (56). Moreover, compelling genetic evidence
from Drosophila suggests that the correct axonal targeting of
photoreceptors depends on ACh synthesis but not on the ex-
pression of VAChT or on synaptic vesicle exocytosis (64).
Hence, at least in Drosophila, a VAChT-independent mecha-
nism of secretion appears to be important during development.
In the light of these findings, we examined whether neuromus-
cular development in mouse embryos depends on the VAChT-
mediated storage of ACh.
Surprisingly, recordings from the diaphragm of VAChTdel/del
mice revealed small MEPPs, raising the possibility that they arise
from small quanta of ACh. Experiments with curare confirmed
that these MEPPs were due to the activation of nAChR. We
tested the possibility that CHT1 can transport ACh, which might
have explained the transport of ACh in vesicles lacking VAChT.
A functional mutant of CHT1 retained on the cytoplasmic mem-
brane was expressed in HEK293 cells, and the transfected cells
were tested for an enhanced uptake of ACh. None was detected.
Moreover, at the low internal pH of synaptic vesicles, CHT1
probably cannot transport substrates (30). We cannot completely
eliminate the possibility that ATP or another vesicular constituent
is released and activates nicotinic receptors, although the block-
ade of the small MEPP by curare indicates that ACh itself is the
agent.
Early work on vesicles isolated from Torpedo electric organs
identified a passive accumulation of ACh that could account
for up to one-third of the total transport (8). More recent
unpublished data indicate that isolated synapse-like mi-
crovesicles loaded with radiolabeled ACh lose their neuro-
transmitter by a VAChT-independent pathway (S. M. Parsons,
personal communication). The experiments suggest that ACh
can permeate vesicular membranes in the absence of active
transport. Given that levels of intracellular ACh are increased
fivefold in VAChTdel/del mice, creating a very large gradient
between the cytoplasm and the lumen of synaptic vesicles, we
favor the possibility that the small MEPPs detected in
VAChTdel/del NMJs result from the passive entry of ACh into
vesicles. In fact, vesicles from VAChTdel/del NMJs can be
loaded with FM1-43, confirming that “empty” vesicles undergo
exocytosis-endocytosis (9, 40). However, a stimulated release
of newly synthesized ACh from brain synaptosomes obtained
from VAChTdel/del mice did not occur, indicating that this
putative passive transport is much less efficient and may re-
quire much more time than the active VAChT-mediated trans-
port.
It seems unlikely that the VAChT-independent secretion of
ACh, as recently detected for Drosophila (64), has a major role
during the development of the mammalian NMJ based on our
assessment of muscle morphology, axonal patterning, MN sur-
vival, and synaptogenesis in VAChTdel/del mice. It is well es-
tablished that the survival of MN, as well as proper axonal and
synaptic targeting, depends on effective competition for neu-
rotrophic support that can be modulated by muscle activity
during embryogenesis. ACh has been recognized to act as a
signal that induces proper axonal branching, nerve terminal
size, and number and maturation of synapses. It likely gener-
ates muscle activity leading to the secretion of neurotrophic
factors during embryonic development (4, 35). The pro-
grammed cell death of MNs is also regulated by ACh, and
FIG. 9. Muscle morphology of E18.5 embryos from VAChTwt/wt, VAChTwt/del, and VAChTdel/del genotypes. Skeletal muscles (gastrocnemius)
were stained with hematoxylin and eosin. Black arrows indicate a loss of normal myofibrillar architecture. Bar, 250 m.
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ChAT-null mice have an increased number of MNs (4, 6, 35).
These results are consistent with the well-known phenomenon
of increased survival of MNs after a pharmacological blockade
of muscle nAChR during development (38, 39, 42). Our ob-
servation that VAChTdel/del mice, despite having a fivefold
increase in tissue ACh levels, have alterations in neuromuscu-
lar development similar to that seen for ChAT-deficient mice
strongly suggests that passive uptake by vesicles or even a
leakage of ACh from nerve terminals cannot compensate for
the lack of VAChT. In fact, the increase in ChAT, CHT1, and
ACh contents should conspire to facilitate ACh leakage in
VAChTdel/del mice but apparently to no avail. It is curious,
however, that the VAChT-independent ACh secretion de-
scribed previously for Drosophila (64) does not operate in the
mammalian NMJ. The difference between mice and flies may
relate to the fact that ACh in Drosophila photoreceptors is not
the chemical transmitter of these synapses as it is for the
mammalian NMJ (64); rather, ACh in the fly photoreceptor
seems to function as a developmental cue, whereas histamine
is the actual neurotransmitter.
Cytoplasmic ACh in the absence of VAChT. We also find
that the removal of the VAChT gene, which is embedded in
the first intron of the ChAT gene, causes several neurochem-
ical alterations in cholinergic synapses. The large increase in
the ACh content is opposite from what happens in mice null
for vesicular monoamine transporter 2, as they have a decrease
in intracellular monoamine contents (62). C. elegans carrying a
blocking mutation of VAChT also has an increase in ACh
contents (29, 65).
The increase in the ACh content in mutant mice is likely due
to increased levels of expression of ChAT and CHT1. The
change in ChAT expression may be related to a compensatory
mechanism due to the lack of ACh release, but it might also
arise from the physical removal of a large fragment of the
ChAT gene, which includes a large part of the first intron (after
the R exon), the N exon, and part of the second intron. This
deletion physically places the M promoter of ChAT close to
the promoter for VAChT and potentially could increase the
level of expression of ChAT mRNAs. However, given the fact
that the CHT1 expression level is also increased, it is possible
that the lack of evoked ACh release triggers signals that up-
regulate the ACh synthesis machinery. Moreover, the increase
in the number of MNs can also contribute to the increased
levels of CHT1 and ChAT in the spinal cord. Given that indi-
vidual synaptic terminals at the NMJ show increased CHT1 ex-
pression levels by immunofluorescence, we favor the possibility
that both increased expression levels and the increased number of
neurons contribute to the higher levels of CHT1 and ChAT. It
remains to be determined if cholinergic neurons in the brain
present similar changes in morphology and sprouting.
Our data suggest that changes in levels of expression of ChAT
and CHT1 “in vivo” can effectively increase the ACh content in
cholinergic terminals. Moreover, it seems that the excess ACh in
the cytoplasm can be accumulated without degradation, suggest-
ing that “in vivo,” this excessive amount of ACh does not impair
ACh synthesis. These results agree with data from previously
reported experiments performed in the presence of the VAChT
inhibitor vesamicol, which, in the superior cervical ganglion, im-
pairs ACh release and allows an accumulation of cytoplasmic
ACh (13). These data suggest that ACh synthesis is not regulated
by mass action, as previously proposed by a number of investiga-
tors (25, 57, 58), because in the absence of ACh release, the
transmitter continues to accumulate.
Previous results indicated that both the exocytosis-endocy-
tosis of synaptic vesicles and the quantal release of the neuro-
transmitter occur in developing axons (24, 34). Our experi-
ments indicate that VAChT regulates a key step for
physiologically relevant neurotransmission during the develop-
ment of the NMJ.
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